{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T17:15:00Z","timestamp":1789146900543,"version":"build-2803163510"},"reference-count":58,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100019091","name":"Key Research and Development Program of Hunan Province of China","doi-asserted-by":"publisher","award":["2025JK2138"],"award-info":[{"award-number":["2025JK2138"]}],"id":[{"id":"10.13039\/501100019091","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004735","name":"Natural Science Foundation of Hunan Province","doi-asserted-by":"publisher","award":["2024JJ8280"],"award-info":[{"award-number":["2024JJ8280"]}],"id":[{"id":"10.13039\/501100004735","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004735","name":"Natural Science Foundation of Hunan Province","doi-asserted-by":"publisher","award":["2025JJ80830"],"award-info":[{"award-number":["2025JJ80830"]}],"id":[{"id":"10.13039\/501100004735","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004735","name":"Natural Science Foundation of Hunan Province","doi-asserted-by":"publisher","award":["2024JJ9272"],"award-info":[{"award-number":["2024JJ9272"]}],"id":[{"id":"10.13039\/501100004735","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lungcancerjournal.info","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.lungcan.2026.109578","type":"journal-article","created":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T23:25:26Z","timestamp":1786663526000},"page":"109578","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Efficacy and prognostic analysis of induction chemoimmunotherapy in unresectable stage \u2162 non\u2013small cell lung cancer: a single-center retrospective study"],"prefix":"10.1016","volume":"220","author":[{"given":"Xia","family":"Gan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhengzheng","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenji","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaowen","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianing","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanxian","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yating","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhongjie","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaning","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Can","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuolong","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuyu","family":"Ouyang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7854-8082","authenticated-orcid":false,"given":"Huai","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.lungcan.2026.109578_b0005","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"issue":"13","key":"10.1016\/j.lungcan.2026.109578_b0010","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1056\/NEJMra0802714","article-title":"Lung cancer","volume":"359","author":"Herbst","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lungcan.2026.109578_b0015","unstructured":"E.S. Amin MB, Greene F, et al, AJCC Cancer Staging Manual. 8thed. Cham, Switzerland: Springer, Cham. , American Joint Commission on Cancer (2017)."},{"issue":"1","key":"10.1016\/j.lungcan.2026.109578_b0020","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.jtho.2015.09.009","article-title":"The IASLC lung cancer staging project: proposals for revision of the TNM stage groupings in the forthcoming (eighth) edition of the TNM classification for lung cancer","volume":"11","author":"Goldstraw","year":"2016","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2026.109578_b0025","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.lungcan.2019.05.027","article-title":"Immune checkpoint-inhibitors and chemoradiation in stage III unresectable non-small cell lung cancer","volume":"134","author":"Melosky","year":"2019","journal-title":"Lung Cancer"},{"issue":"24","key":"10.1016\/j.lungcan.2026.109578_b0030","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1056\/NEJMoa1809697","article-title":"Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC","volume":"379","author":"Antonia","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.lungcan.2026.109578_b0035","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/S1470-2045(21)00630-6","volume":"23","author":"Zhou","year":"2022","journal-title":"Lancet Oncol."},{"issue":"5","key":"10.1016\/j.lungcan.2026.109578_b0040","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.resinv.2019.03.011","article-title":"Patients with unresectable stage III non-small cell lung cancer eligible to receive consolidation therapy with durvalumab in clinical practice based on PACIFIC study criteria","volume":"57","author":"Sakaguchi","year":"2019","journal-title":"Respir. Investig."},{"issue":"9","key":"10.1016\/j.lungcan.2026.109578_b0045","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1016\/j.annonc.2022.06.013","article-title":"Immunotherapy in unresectable stage III non-small-cell lung cancer: state of the art and novel therapeutic approaches","volume":"33","author":"Cortiula","year":"2022","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.lungcan.2026.109578_b0050","article-title":"Selective personalized radioimmunotherapy for locally advanced non-small-cell lung cancer trial","author":"Ohri","year":"2023","journal-title":"J. Clin. Oncol."},{"issue":"17","key":"10.1016\/j.lungcan.2026.109578_b0055","doi-asserted-by":"crossref","first-page":"3236","DOI":"10.1200\/JCO.22.02575","article-title":"Neoadjuvant checkpoint immunotherapy and melanoma: the time is now","volume":"41","author":"Long","year":"2023","journal-title":"J. Clin. Oncol."},{"issue":"21","key":"10.1016\/j.lungcan.2026.109578_b0060","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1056\/NEJMoa2202170","article-title":"Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer","volume":"386","author":"Forde","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lungcan.2026.109578_b0065","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1591134","article-title":"Induction chemoimmunotherapy may achieve non-inferior outcomes to consolidation immunotherapy in patients with unresectable stage III NSCLC: a real-world multicenter retrospective study","volume":"16","author":"Guan","year":"2025","journal-title":"Front. Immunol."},{"issue":"9","key":"10.1016\/j.lungcan.2026.109578_b0070","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1001\/jamaoncol.2024.1897","article-title":"Atezolizumab before and after chemoradiation for unresectable stage iii non-small cell lung cancer: a phase ii nonrandomized controlled trial","volume":"10","author":"Ross","year":"2024","journal-title":"JAMA Oncol."},{"issue":"2","key":"10.1016\/j.lungcan.2026.109578_b0075","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/nri3789","article-title":"Immune cell promotion of metastasis","volume":"15","author":"Kitamura","year":"2015","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.lungcan.2026.109578_b0080","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.688625","article-title":"The role of tumor inflammatory microenvironment in lung cancer","volume":"12","author":"Tan","year":"2021","journal-title":"Front. Pharmacol."},{"issue":"8","key":"10.1016\/j.lungcan.2026.109578_b0085","doi-asserted-by":"crossref","first-page":"2282","DOI":"10.1002\/ijc.32274","article-title":"Leukocytosis and neutrophilia as independent prognostic immunological biomarkers for clinical outcome in the CAO\/ARO\/AIO-04 randomized phase 3 rectal cancer trial","volume":"145","author":"Diefenhardt","year":"2019","journal-title":"Int. J. Cancer"},{"issue":"6","key":"10.1016\/j.lungcan.2026.109578_b0090","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1159\/000475911","article-title":"Prognostic significance of neutrophil-to-lymphocyte ratio in ovarian cancer: a systematic review and meta-analysis of observational studies","volume":"41","author":"Huang","year":"2017","journal-title":"Cell. Physiol. Biochem."},{"issue":"26","key":"10.1016\/j.lungcan.2026.109578_b0095","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000034180","article-title":"Prognostic significance of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in non-small cell lung cancer","volume":"102","author":"Bayraktaroglu","year":"2023","journal-title":"Medicine (Baltimore)"},{"issue":"2","key":"10.1016\/j.lungcan.2026.109578_b0100","doi-asserted-by":"crossref","first-page":"128","DOI":"10.5152\/tjg.2022.22203","article-title":"Prognostic significance of hemoglobin\/prognostic nutritional index and hemoglobin\/red blood cell distribution in rectal cancer","volume":"34","author":"Tuncel","year":"2023","journal-title":"Turk. J. Gastroenterol."},{"issue":"1","key":"10.1016\/j.lungcan.2026.109578_b0105","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.radonc.2018.02.023","article-title":"ESTRO ACROP guidelines for target volume definition in the treatment of locally advanced non-small cell lung cancer","volume":"127","author":"Nestle","year":"2018","journal-title":"Radiother. Oncol."},{"issue":"5","key":"10.1016\/j.lungcan.2026.109578_b0110","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1001\/jamaoncol.2021.0366","article-title":"Tislelizumab plus chemotherapy vs chemotherapy alone as first-line treatment for advanced squamous non-small-cell lung cancer: a phase 3 randomized clinical trial","volume":"7","author":"Wang","year":"2021","journal-title":"JAMA Oncol."},{"issue":"3","key":"10.1016\/j.lungcan.2026.109578_b0115","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/S2213-2600(20)30365-9","article-title":"Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial","volume":"9","author":"Zhou","year":"2021","journal-title":"Lancet Respir. Med."},{"issue":"1","key":"10.1016\/j.lungcan.2026.109578_b0120","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1038\/s41392-025-02408-3","article-title":"Consolidative nivolumab versus observation in unresectable stage III non-small cell lung cancer patients following neoadjuvant nivolumab plus chemotherapy and concurrent chemoradiotherapy (CA209-7AL): a randomized clinical trial","volume":"10","author":"Qiu","year":"2025","journal-title":"Signal Transduct. Target. Ther."},{"issue":"9","key":"10.1016\/j.lungcan.2026.109578_b0125","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1001\/jamaoncol.2021.2301","article-title":"Pembrolizumab plus concurrent chemoradiation therapy in patients with unresectable, locally advanced, stage iii non-small cell lung cancer: the phase 2 KEYNOTE-799 nonrandomized trial","volume":"7","author":"Jabbour","year":"2021","journal-title":"JAMA Oncol."},{"issue":"10","key":"10.1016\/j.lungcan.2026.109578_b0130","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1016\/j.jtho.2020.07.014","article-title":"Efficacy and safety of sintilimab plus pemetrexed and platinum as first-line treatment for locally advanced or metastatic nonsquamous NSCLC: a randomized, double-blind, phase 3 study (oncology pRogram by InnovENT anti-PD-1-11)","volume":"15","author":"Yang","year":"2020","journal-title":"J. Thorac. Oncol."},{"issue":"6","key":"10.1016\/j.lungcan.2026.109578_b0135","doi-asserted-by":"crossref","DOI":"10.1016\/j.medj.2025.100574","article-title":"Toripalimab plus platinum-doublet chemotherapy as perioperative therapy for initially unresectable NSCLC: an open-label, phase 2 trial","volume":"6","author":"Zeng","year":"2025","journal-title":"Med"},{"issue":"3","key":"10.1016\/j.lungcan.2026.109578_b0140","doi-asserted-by":"crossref","first-page":"e143","DOI":"10.1016\/S1470-2045(17)30074-8","article-title":"iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics","volume":"18","author":"Seymour","year":"2017","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.lungcan.2026.109578_b0145","unstructured":"T.C. R, R: A Language and Environment for Statistical Computing, R Foundation for Statistical Computing, Vienna, Austria. https:\/\/www.R-project.org\/."},{"key":"10.1016\/j.lungcan.2026.109578_b0150","doi-asserted-by":"crossref","DOI":"10.1016\/j.lungcan.2025.108883","article-title":"Neoadjuvant immunotherapy plus chemotherapy in locally advanced stage III NSCLC patients undergoing definitive chemo-radiotherapy\u2013-a real-world multicenter retrospective study","volume":"211","author":"Li","year":"2026","journal-title":"Lung Cancer"},{"key":"10.1016\/j.lungcan.2026.109578_b0155","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1602082","article-title":"Induction immunochemotherapy followed by definitive chemoradiotherapy and consolidation immunotherapy for unresectable stage III non-small cell lung cancer: a multi-institutional retrospective cohort study","volume":"16","author":"Fu","year":"2025","journal-title":"Front. Immunol."},{"issue":"4","key":"10.1016\/j.lungcan.2026.109578_b0160","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1002\/ijc.70162","article-title":"Real-world effectiveness and safety of treatment strategies for unresectable, driver-negative Stage III NSCLC: a retrospective multicentre study","volume":"158","author":"Xu","year":"2026","journal-title":"Int. J. Cancer"},{"issue":"4","key":"10.1016\/j.lungcan.2026.109578_b0165","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1038\/s41591-020-0829-0","article-title":"Learning from clinical trials of neoadjuvant checkpoint blockade","volume":"26","author":"Versluis","year":"2020","journal-title":"Nat. Med."},{"issue":"7652","key":"10.1016\/j.lungcan.2026.109578_b0170","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1038\/nature22079","article-title":"T-cell invigoration to tumour burden ratio associated with anti-PD-1 response","volume":"545","author":"Huang","year":"2017","journal-title":"Nature"},{"issue":"11","key":"10.1016\/j.lungcan.2026.109578_b0175","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1038\/s41591-018-0198-0","article-title":"Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma","volume":"24","author":"Blank","year":"2018","journal-title":"Nat. Med."},{"issue":"7","key":"10.1016\/j.lungcan.2026.109578_b0180","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1038\/nrc3958","article-title":"The tumour microenvironment after radiotherapy: mechanisms of resistance and recurrence","volume":"15","author":"Barker","year":"2015","journal-title":"Nat. Rev. Cancer"},{"issue":"6","key":"10.1016\/j.lungcan.2026.109578_b0185","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.semcancer.2004.06.006","article-title":"Inflammation as a tumor promoter in cancer induction","volume":"14","author":"Philip","year":"2004","journal-title":"Semin. Cancer Biol."},{"issue":"6","key":"10.1016\/j.lungcan.2026.109578_b0190","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.it.2005.04.003","article-title":"Inflammation-associated cancer: NF-kappaB is the lynchpin","volume":"26","author":"Li","year":"2005","journal-title":"Trends Immunol."},{"issue":"1","key":"10.1016\/j.lungcan.2026.109578_b0195","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/s41571-025-01080-4","article-title":"Unresectable stage III non-small-cell lung cancer: state of the art and challenges","volume":"23","author":"Remon","year":"2026","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.lungcan.2026.109578_b0200","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.semradonc.2019.12.003","article-title":"Lymphocyte-sparing radiotherapy: the rationale for protecting lymphocyte-rich organs when combining radiotherapy with immunotherapy","volume":"30","author":"Lambin","year":"2020","journal-title":"Semin. Radiat. Oncol."},{"issue":"5","key":"10.1016\/j.lungcan.2026.109578_b0205","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1016\/j.ijrobp.2019.08.047","article-title":"Impact of treatment-related lymphopenia on immunotherapy for advanced non-small cell lung cancer","volume":"105","author":"Cho","year":"2019","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"21","key":"10.1016\/j.lungcan.2026.109578_b0210","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1056\/NEJMoa2202170","article-title":"Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer","volume":"386","author":"Forde","year":"2022","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.lungcan.2026.109578_b0215","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1056\/NEJMoa2302983","article-title":"Perioperative pembrolizumab for early-stage non-small-cell lung cancer","volume":"389","author":"Wakelee","year":"2023","journal-title":"N. Engl. J. Med."},{"issue":"18","key":"10.1016\/j.lungcan.2026.109578_b0220","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1056\/NEJMoa2304875","article-title":"Perioperative durvalumab for resectable non-small-cell lung cancer","volume":"389","author":"Heymach","year":"2023","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.lungcan.2026.109578_b0225","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1001\/jama.2023.24735","article-title":"Perioperative toripalimab plus chemotherapy for patients with resectable non-small cell lung cancer: the neotorch randomized clinical trial","volume":"331","author":"Lu","year":"2024","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.lungcan.2026.109578_b0230","doi-asserted-by":"crossref","first-page":"10124","DOI":"10.1038\/s41467-025-66097-w","article-title":"Induction chemo-immunotherapy followed by chemo-radiotherapy and immunotherapy maintenance in stage III NSCLC (APOLO): a phase 2 trial","volume":"16","author":"Provencio","year":"2025","journal-title":"Nat. Commun."},{"issue":"7","key":"10.1016\/j.lungcan.2026.109578_b0235","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1016\/j.ccell.2024.05.024","article-title":"Neoadjuvant SHR-1701 with or without chemotherapy in unresectable stage III non-small-cell lung cancer: a proof-of-concept, phase 2 trial","volume":"42","author":"Zhou","year":"2024","journal-title":"Cancer Cell"},{"issue":"7","key":"10.1016\/j.lungcan.2026.109578_b0240","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1200\/JCO.19.01162","article-title":"Long-term results of NRG oncology RTOG 0617: standard- versus high-dose chemoradiotherapy with or without cetuximab for unresectable stage iii non\u2013small-cell lung cancer","volume":"38","author":"Bradley","year":"2019","journal-title":"J. Clin. Oncol."},{"issue":"12","key":"10.1016\/j.lungcan.2026.109578_b0245","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1200\/JCO.21.01308","article-title":"Five-year survival outcomes from the PACIFIC trial: durvalumab after chemoradiotherapy in stage III non\u2013small-cell lung cancer","volume":"40","author":"Spigel","year":"2022","journal-title":"J. Clin. Oncol."},{"issue":"12","key":"10.1016\/j.lungcan.2026.109578_b0250","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1158\/2159-8290.CD-16-0577","article-title":"Improved efficacy of neoadjuvant compared to adjuvant immunotherapy to eradicate metastatic disease","volume":"6","author":"Liu","year":"2016","journal-title":"Cancer Discov."},{"issue":"8","key":"10.1016\/j.lungcan.2026.109578_b0255","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1007\/s00066-018-1309-z","article-title":"Tumor volume as aprognostic marker in p16-positive and p16-negative oropharyngeal cancer patients treated with definitive intensity-modulated radiotherapy","volume":"194","author":"Carp\u00e9n","year":"2018","journal-title":"Strahlenther. Onkol."},{"issue":"3","key":"10.1016\/j.lungcan.2026.109578_b0260","doi-asserted-by":"crossref","first-page":"861","DOI":"10.4143\/crt.2017.237","article-title":"Combination of tumor volume and epstein-barr virus DNA improved prognostic stratification of stage ii nasopharyngeal carcinoma in the intensity modulated radiotherapy era: a large-scale cohort study","volume":"50","author":"Chen","year":"2018","journal-title":"Cancer Res. Treat."},{"issue":"12","key":"10.1016\/j.lungcan.2026.109578_b0265","doi-asserted-by":"crossref","DOI":"10.1088\/1361-6560\/ac047e","article-title":"Tumor control probability in hypofractionated radiotherapy as a function of total and hypoxic tumor volumes","volume":"66","author":"Chvetsov","year":"2021","journal-title":"Phys. Med. Biol."},{"issue":"10","key":"10.1016\/j.lungcan.2026.109578_b0270","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1016\/j.jtho.2020.06.008","article-title":"Radiotherapy-related lymphopenia affects overall survival in patients with lung cancer","volume":"15","author":"Abravan","year":"2020","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2026.109578_b0275","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.radonc.2020.09.002","article-title":"Radiation-induced lymphopenia during chemoradiation therapy for non-small cell lung cancer is linked with age, lung V5, and XRCC1 rs25487 genotypes in lymphocytes","volume":"154","author":"Xie","year":"2021","journal-title":"Radiother. Oncol."},{"key":"10.1016\/j.lungcan.2026.109578_b0280","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1426635","article-title":"Early lymphocyte levels and low doses radiation exposure of lung predict lymphopenia in radiotherapy for lung cancer","volume":"15","author":"Kuncman","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.lungcan.2026.109578_b0285","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.radonc.2020.12.019","article-title":"Proton beam therapy reduces the risk of severe radiation-induced lymphopenia during chemoradiotherapy for locally advanced non-small cell lung cancer: a comparative analysis of proton versus photon therapy","volume":"156","author":"Kim","year":"2021","journal-title":"Radiother. Oncol."},{"key":"10.1016\/j.lungcan.2026.109578_b0290","article-title":"Immune system dose with proton versus photon radiotherapy for treatment of locally advanced NSCLC","volume":"12","author":"Patel","year":"2024","journal-title":"Int J Part Ther"}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500226006392?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500226006392?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T16:55:42Z","timestamp":1789145742000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500226006392"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":58,"alternative-id":["S0169500226006392"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2026.109578","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and prognostic analysis of induction chemoimmunotherapy in unresectable stage \u2162 non\u2013small cell lung cancer: a single-center retrospective study","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2026.109578","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"109578"}}